Sartorius Stedim: Quarterly EPS more than halved
The supplier of products and services to the pharmaceutical industry posted sales of €667 million, down 6.7% at constant exchange rates, but booked orders of €676 million, up 13.9% at constant exchange rates.
For the current year, SSB continues to anticipate a gradual recovery in business as the quarters go by, and expects sales growth "in the mid- to high-single digits", as well as a current EBITDA margin in excess of 30%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction